Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary Tumor Resection with Sintilimab and Chemotherapy in Advanced NSCLC
NCT07177105Phase 2Not yet recruiting
- Start
- Sep 2025
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of sintilimab in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-Free Survival up to 5 years. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07177105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07177105.